Compare Trip.com Group Ltd (TCOM) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Trip.com Group Ltd vs TG Therapeutics Inc — how do they compare? Trip.com Group Ltd trades at $45.64 (market cap $29.10B), while TG Therapeutics Inc trades at $49.56 (market cap $7.64B). The key difference: Trip.com Group Ltd is far larger — about 3.8× TG Therapeutics Inc's market cap, and Trip.com Group Ltd pays a 0.42% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| TCOM | TGTX | |
|---|---|---|
Market Cap | $29.10B | $7.64B |
Sector | Consumer Cyclical | Health |
52-Week High | $78.96 | $59.06 |
52-Week Low | $39.84 | $26.94 |
Enterprise Value | $21.75B | $7.84B |
Dividend Yield | 0.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Trip.com Group Limited (TCOM) trades at $45.70, down 3.01% over 24 hours, reflecting recent bearish technical signals. The company reported strong annual revenue growth to $62.41 billion in 2025 with a net income margin of 53.34%, but faces headwinds from a recent $770 million antitrust penalty in China and softer Q2 2026 revenue guidance. Valuation ratios appear attractive with a P/E of 6.89 and EV/EBITDA of 3.76, while analyst consensus remains bullish with a $59.29 price target.
The stock presents a value opportunity given low valuation multiples and robust profitability, but near-term performance is clouded by regulatory scrutiny and earnings misses. Investors must weigh the company's solid cash flow generation and market position against regulatory risks and competitive pressures in the travel sector.
TGTX trades at $50.26, up 2.24% in the last session, with a bearish technical signal from moving averages despite neutral oscillators. Recent Q2 2026 earnings missed estimates at $0.05 per share versus $0.3057 expected, though revenue surged to $240 million, driven by strong BRIUMVI sales growth of 64% year-over-year. The company raised 2026 revenue guidance to $950 million, reflecting robust demand for its multiple sclerosis treatment.
The outlook is mixed: strong revenue growth and a high analyst buy consensus (84.62%) support upside to the $63.75 price target, but earnings misses, a high EV/EBITDA of 56.26, and a shareholder investigation into fiduciary breaches pose risks. Investors should weigh the growth potential against execution and regulatory uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Trip.com Group Ltd
Trip.com is the largest online travel agent in China and is positioned to benefit from the country's rising demand for higher-margin outbound travel as passport penetration is only 12% in China. The company generated about 78% of sales from accommodation reservations and transportation ticketing in 2020. The rest of revenue comes from package tours and corporate travel. Prior to the pandemic in 2019, the company generated 25% of revenue from international business, which is important to its margin expansion. Most of sales come from websites and mobile platforms, while the rest come from call centers. The competes in a crowded OTA industry in China, including Meituan, Alibaba-backed Fliggy, Toncheng, and Qunar. The company was founded in 1999 and listed on the Nasdaq in December 2003.
Read more on TCOM →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
